Post expresses bullish sentiment on IBRX, citing 700% annual revenue growth from cancer drug ANKTIVA and innovation.
IBRX — LONG The author is bullish on IBRX, citing 700% annual revenue growth fueled by cancer drug ANKTIVA and continued innovation. The thesis is that the company's growth trajectory and pipeline will drive the stock higher.
IBRX looking to continue to have very promising growth after cancer drug ANKTIVA fuels 700% annual revenue growth.
This Reddit post, published January 15, 2026, features u/Sea-Spite-7234 discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Sea-Spite-7234 · Tickers: IBRX